Category: Psoriasis

Description

This page contains brief details about the drug secukinumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Secukinumab is a monoclonal antibody (protein which attaches to a specific target) which was approved for its medical use on 10th November 2014.

Mechanism of Action of Secukinumab

Secukinumab Injection is a biological agent that belongs to the group of human IgG1 monoclonal antibody. Secukinumab specifically targets and binds to the interleukin 17A cytokine. Interleukin 17A is an inflammatory mediator that is present in high concentrations in inflammatory diseases. Secukinumab blocks the interaction of this protein with its receptors and eventually lower the inflammatory effects.

Uses of Secukinumab

Secukinumab Injection has been developed to treat various inflammatory conditions like plaque psoriasis, psoriatic arthritis, radiographic and non-radiographic axial spondyloarthritis and ankylosing spondylosis.

Secukinumab Dosage available

Secukinumab is available as a powder for solution for injection in the dose 150mg, intended for subcutaneous administration. For adults with plaque psoriasis and psoriatic arthritis, the recommended dose is 300mg subcutaneous injection once a week for 4 weeks. For paediatric patients and adults with axial spondyloarthritis, the recommended dose is 150mg once a week for 4 weeks.